Golden Biotechnology Corporation Stock price

Equities

4132

TW0004132006

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
31.6 TWD +1.61% Intraday chart for Golden Biotechnology Corporation -4.10% -19.49%
Sales 2021 81.77M 2.56M Sales 2022 218M 6.81M Capitalization 8.55B 267M
Net income 2021 -444M -13.88M Net income 2022 -272M -8.5M EV / Sales 2021 204 x
Net cash position 2021 438M 13.71M Net cash position 2022 239M 7.47M EV / Sales 2022 38.1 x
P/E ratio 2021
-38.7 x
P/E ratio 2022
-31.4 x
Employees 122
Yield 2021 *
-
Yield 2022
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients CI
Golden Biotechnology Corporation Receives Antroquinonol Oral Covid-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe Covid-19 Patients CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2020 CI
GoldenBiotech's New Drug Antroquinonol Trial Receives Positive Response from DMC Review and Licenses for 4 Countries CI
Golden Biotechnology Corp. Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Golden Biotechnology Corp. Announces it's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2019 CI
More news
1 day+1.61%
1 week-4.10%
Current month-21.20%
1 month-18.35%
3 months-18.77%
6 months-25.38%
Current year-19.49%
More quotes
1 week
30.55
Extreme 30.55
33.15
1 month
27.55
Extreme 27.55
41.75
Current year
27.55
Extreme 27.55
43.85
1 year
27.55
Extreme 27.55
71.40
3 years
27.55
Extreme 27.55
335.00
5 years
25.71
Extreme 25.71
335.00
10 years
23.66
Extreme 23.66
335.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 19-03-03
Founder - 02-09-26
Director of Finance/CFO - -
Members of the board TitleAgeSince
Founder - 02-09-26
Founder - 02-09-26
Director/Board Member - 09-06-25
More insiders
Date Price Change Volume
24-03-27 31.6 +1.61% 477 370
24-03-27 31.1 -2.51% 565,763
24-03-26 31.9 -3.48% 465,023
24-03-25 33.05 +2.01% 286,100
24-03-22 32.4 +0.62% 421,511

End-of-day quote Taipei Exchange, March 27, 2024

More quotes
Golden Biotechnology Corp is a Taiwan-based company mainly engaged in the development of new anti-cancer drugs. The Company's main development projects are novel compounds of Antroquinonol for the treatment of non-small cell lung cancer, acute myeloid leukemia, pancreatic cancer, hyperlipidemia, hepatitis B, and Corona Virus Disease 2019 (Covid-19), which are broadly effective small molecule drugs with no systemic toxicity. The Company is also engaged in the manufacture and sales of health foods and dietary supplements. The main products include antrodia camphorata mycelium capsules and others. The Company sells products in the Taiwan market as well as in other areas of Asia.
More about the company
  1. Stock
  2. Equities
  3. Stock Golden Biotechnology Corporation - Taipei Exchange